BEVA has announced that tickets are now on sale for BEVA Congress and members who register before 4th August 2016 can benefit from big discounts.
This year, BEVA Congress is being held at the ICC in central Birmingham.
In addition to the clinical programme, tactics to achieve the elusive work life balance and the applicability of evidence based medicine are recurring themes over the three days of the event.
Five separate programmes will run concurrently in five adjacent halls, deploying a mix of traditional lectures, panel discussions and interactive forums to suit equine vets and mixed practitioners at any stage in their career. Vet nurses, farriers, equine physiotherapists and equine dental technicians can also attend specific sessions focused on their areas of expertise.
There will be daily practical sessions in the exhibition hall: Jonathan Anderson, Will Barker, Tim Barnett, Ollie Crowe, Richard Reardon, Neil Townsend and Thomas Witte will be demonstrating sinoscopy and gastroscopy techniques and delegates will have the chance to roll up their sleeves and get hands on with dead heads and digital models.
Programme highlights include a day of advanced orthopaedics in combination with the European Society of Veterinary Orthopaedics and Traumatology (ESVOT). The sessions will draw on canine and human experience, with speakers including Ian Wright from the Newmarket Equine Hospital, Peter Clegg from the University of Liverpool, Wayne McIlwraith from Colorado State University and Martin Waselau from Equine Hospital Aschheim, Germany.
There will also be career and practice development sessions exploring what you can do with your veterinary degree, how to look after your staff and how to take advantage of smartphone technology in practice. Evidence in surgery and critical appraisal tools will be explored in a series of presentations on two separate days across a wide range of conditions. Speakers will include Will Barker, Bruce McGorum, and Etienne O'Brien.
Kathy Clarke, Professor of Veterinary Anaesthesia at the Royal Veterinary College, will be giving the plenary lecture on from the difficult horse to the demanding surgeon; how effective sedation has revolutionised what is achievable in equine clinical practice. There will be a debate on the Friday with Victoria Harris chairing the promisingly divisive This house believes that lab tests are overused and abused.
There will also be comprehensive sessions on parasitology, laminitis, skin disease, anaesthesia and analgesia, colic, respiratory disease, sports injuries, standing surgery, ophthalmology, diagnostics, wounds, neurology and differentiating lameness from neurological disease, mare and foal, reproduction, dentistry, gastro intestinal disease and nutrition, cardiology and medicine.
Saturday’s vet nurse sessions will cover surgical management, emergency patients, the use of antimicrobials and adjunctive therapies. In addition, daily clinical research presentations will provide exclusive opportunities to hear about novel and exciting research projects.
There's a free BEVA Congress App with the full scientific programme and to help you manage your day. And if you are struggling for time or torn between several lectures you can use the BEVA Congress Encore Room which gives you the chance to play back missed lectures at your convenience.
For more information, visit www.beva.org.uk.
The 2020 OV Conference will offer up to 25 hours of CPD with lectures, workshops and Q&A sessions from world-class speakers in streams covering small animals, farm animals and equines. There will also be exclusive offers from industry sponsors and online networking opportunities.
The OV Conference provides an opportunity for OVs to discuss current topics of interest and recent developments in their work. Themes this year will include notifiable diseases, biosecurity and disease control, and export certification.
In addition to the live lectures, delegates will be able to view recordings of all the sessions on-demand for three months following the conference. The CPD on offer counts towards OV revalidation qualifications with the event open to all vets, as well as animal health paraprofessionals, nurses and practice managers.
David Babington MRCVS, Business Development Director at Improve International, said: "Moving the OV Conference online has given us an opportunity to harness the technology we use regularly in all of our veterinary training to bring OVs an exceptional but affordable CPD experience.
"Our excellent speakers are looking forward to sharing the latest updates in all aspects of OV work with our delegates and to discussing the challenges ahead, particularly in the light of the COVID-19 pandemic and with the UK moving inexorably towards leaving the EU at the end of the year.
"We’re looking forward to meeting our delegates old and new online at the OV Conference in September.”
The full programme and tickets are now available from https://officialvet.com
The first 150 tickets will get an ‘Early Bird’ 25% discount from £160 to £120+ VAT using the code UK.OV.EARLYBIRD.
"Advances in Imaging of the Equine Distal Limb 2017–2022" comprises a total of 20 papers which have been selected by Mathieu Spriet, Ann Carstens and Tim Mair.
It also includes an editorial from the EVJ summarising the major historical technological developments in imaging of the foot and fetlock.
The publication looks at the evolution of computed tomography (CT), positron emission tomography (PET), which has opened a whole new field of possibilities for bone and soft tissue imaging in racehorses and sport horses, MRI and how it has been improved by optimising scanning techniques, ultrasound radiography and scintigraphy.
Mathieu Spriet said: “The content of this virtual issue represents an amazing amount of new knowledge that with no doubt will contribute to improve equine welfare and safety.
“With the increase availability and versatility of all the imaging modalities, the knowledge base appears to increase exponentially.
"We are very excited to see what the next five years will bring. We hope the readers will enjoy consulting this collection as much as we enjoyed putting it together.”
The virtual issue is free for 12 weeks and can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.equine-distal-limb
Photo: 18F-NaF PET, CT and MRI images from a horse with navicular and middle phalanx lesions. Adapted from EVJ 2018;50: 125-132
The 'Vet REACT Colic Champions', which is being supported by 62 veterinary practices around the country, will help horse owners create a plan of action if their horse develops critical colic and needs referral to an equine hospital.
The campaign follows research conducted by the University of Nottingham which found that one in three emergency call-outs by vets were due to colic and 90% of owners were not confident in spotting its early signs.
Emmeline Hannelly, Welfare Education Manager at the BHS said: "It’s fantastic that so many vets are supporting our 'Vet REACT Colic Champions' scheme – we are delighted to be working with them. We hope that it will help even more owners to make informed decisions related to colic and in turn, improve equine welfare.”
Sarah Freeman, Professor of Veterinary Surgery at the School of Veterinary Science and Medicine, University of Nottingham said: "We are delighted to be working with vet practices on the 'Vet REACT Colic Champions' scheme. Their support and guidance has been a huge help in reaching such a wide population and we hope we can reach even more people in the future."
Alex Kingdon, BVM BVS MRCVS from Avonvale Equine Practice said: "Being part of the 'Vet REACT Colic Champions' scheme is incredibly important to our practice. Colic is by far one of the most common emergency conditions we see and the scheme has already had a huge impact on many horse owners.”
For further details on the 'Vet REACT Colic Champions' scheme and 'React Now to Beat Colic' campaign, visit: www.bhs.org.uk/colic
Photo: Shutterstock/PJ Photography
Alstoe Animal Health has introduced a new, palatable joint nutrient supplement for horses.
According to the company, the benefits of feeding equine joint nutrient supplements to assist with maintaining mobility and supporting health joint function has been well documented, but until now, their flavours have often had to be disguised by mixing them into the feed in an attempt to ensure compliance.
Easeflex Equine palatable pellets include alfalfa, an equine favourite which has been used in the USA for some time, and shown to be readily accepted by horses, without the need to mix with the feed.
Alstoe says Easeflex Equine contains high levels of glucosamine hydrochloride and chondroitin sulphate, which are important in the production of glycosaminoglycans, and which have chondroprotective properties that aid in the natural renewal of cartilaginous tissue. Easeflex Equine palatable pellets also include MSM (methyl-sulphonyl-methane), a source of bioavailable sulphur, a key component of connective tissue and important in the synthesis of articular cartilage. Antioxidants are also present to help prevent damage by free radicals, as well as the essential trace minerals, copper, zinc and manganese.
Easeflex Equine palatable pellets can be fed to horses, ponies and donkeys of any age. The company recommends initial daily feeding of a double loading quantity for the first four to six weeks, thereafter reducing to a maintenance level or as directed by the veterinary surgeon. The amount of pellets to be fed depends on the weight of the animal, one small scoop containing 28g of pellets can be a daily dose for a horse of up to 450kg. Easeflex Equine palatable pellets are available in 1.7kg and 4.54kg tubs.
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
The National Equine Health Survey is an online snapshot survey designed to uncover common health issues in horses, directly from horse owners themselves. Results of the survey are used to build a picture of equine health and disease in the UK and define priorities for future research, training and education.
Over the past six years the survey, in partnership with the British Equine Veterinary Association, has developed to become one of the UK’s most important endemic disease monitoring initiative. The results are referenced in leading veterinary and equestrian publications and papers and are regarded as valuable benchmarks for our general knowledge of horse health.
Blue Cross Education Officer Gemma Taylor said: "These majestic police horses have taken part in our survey and we hope that they will encourage others to follow suit and be ambassadors for horse welfare.
"The more data we can collect from the National Equine Health Survey the more robust our results will be, helping us to steer equine awareness, education and research to keep our nation’s horses healthier."
Last year survey records were returned for almost 17,000 horses, ponies, donkeys and mules and the six most notable disease syndromes identified.
To take part in the National Equine Health Survey, visit: www.bluecross.org.uk/NEHS
To find out more about Blue Cross’s rescue and rehoming work with horses and ponies visit bluecross.org.uk
Fort Dodge Animal Health has announced that its Duvaxyn WNV vaccine against West Nile Virus (WNV) is now available in the UK, following its licensing through the European Medicines Agency (EMEA).
Duvaxyn WNV is the first vaccine available in Europe to protect horses against this emerging disease threat. 288 horses and two people in Italy were found to be infected with WNV during the outbreak that hit northern Italy in late 2008 where it is now considered endemic. The disease is endemic in all areas of North America where it has claimed the lives of both horses and humans.
West Nile Virus is caused by a highly contagious flavivirus, which is transmitted by mosquitoes, primarily of the Culex species. The natural hosts of West Nile virus are birds, with migratory birds from Africa carrying the disease. Mosquitoes become infected after taking a blood meal from infected birds and then may transmit the disease to horses and even humans. While horses are 'dead end hosts,' the consequences can be severe as the virus causes encephalitis or meningitis. Mortality rates among horses which develop neurological signs are high and there is no palliative cure for the disease. Treatment is limited to symptomatic relief which can be long and expensive.
Sabrina Jordan, UK Business Manager for Equine Vaccines at Fort Dodge said: "WNV is an increasing threat to the equestrian sector in the UK and is a particular challenge for owners who transport their horses around the world.
"The fact that a vaccine is now available will undoubtedly offer peace of mind to the equestrian community. They can be reassured that horses in the UK can now be vaccinated against WNV with a vaccine that has already been shown to be highly effective in protecting horses in America.
"With any vaccine, a record that a horse has been vaccinated with Duvaxyn WNV should be recorded in its horse passport. By presenting this vaccine in pre-filled syringes with Infovax-ID labels, we've aimed to make both the administration and record keeping of Duvaxyn WNV as convenient as possible.
"To build understanding of this potentially fatal disease threat, we are continuing to work with governments and authorities at a national and European level, as well as working in partnership with the UK's veterinary community to ensure that owners are fully informed about the risk WNV poses and of the benefits of vaccination."
Equistro® has produced a dust-free pelleted presentation of Secreta Pro, following requests from clients. Secreta Pro-Max® was launched to vets at BEVA Congress.
Secreta Pro is a respiratory supplement used to support the bronchial system and natural defences on a long term basis.
For more information on Secreta Pro-Max® and all Equistro products, please visit http://www.equistro.co.uk/, or contact your Vetoquinol representative.
The Veterinary Wound Healing Association (VWHA) has become the third veterinary association to make a new home on VetSurgeon.org.
VWHA President Jacintha Wilmink said: "We're very excited about joining VetSurgeon.org and how it will allow our members to connect with each other and share information quicker and more easily than ever before".
In common with the other associations, the VWHA is making its content available for all VetSurgeon members to access, however only VWHA members can submit cases to its section for discussion, or participate in the VWHA forum. Jacintha added: "We hope that the cases and discussions in our section of the site will be of value to all practitioners, and that many more of you will want to join the association and participate".
Information about the benefits of joining the VWHA is available here.
He takes over the role from Huw Griffiths at the end of BEVA Congress 7th -10th September 2022. Roger Smith becomes President Elect.
Following graduation from The University of Bristol in 2001, David worked in farm animal and equine practice in Somerset before completing an internship at Liphook Equine Hospital.
A three-year Horserace Betting Levy Board residency at The University of Glasgow and Liphook Equine Hospital enabled him to train as a specialist in equine internal medicine and to gain a masters by research into equine asthma and an RCVS certificate in equine medicine.
David spent several years at Liphook Equine Hospital in Hampshire and had spells at The Royal Veterinary College, London and Charles Sturt University in Australia before moving to Rainbow Equine Hospital in Yorkshire where he led the internal medicine and laboratory services as a director and subsequently a clinical director following the hospital’s acquisition by the VetPartners group.
David returned to his Westcountry roots in 2020 and now combines work as an independent equine medicine and therapeutics consultant with running the family farm on the edge of Exmoor.
He is chair of BEVA’s health and medicines committee.
During his presidential year David is keen to continue build on his recent work around antimicrobial and anthelmintic resistance as well as expanding BEVA’s global outreach to support more equine vets and have a greater impact on equine welfare.
He said: “I’ve had a great time being part of the profession for the past 20 years and I am now in a position to give something back.
“Huw has driven much activity in the past year around recruitment and retention and I hope to be able to build on this and action results from the recent survey, under Huw’s continued supervision. I am also determined to maintain momentum around BEVA’s antimicrobial and anthelmintic resistance work as well as step up collaboration internationally on these and other projects to extend BEVA’s global outreach.
“Around 99% of the world’s horses are cared for by around 1% of the world’s vets so we are not going to change things overnight; however, BEVA has so much to offer and we should use our resources to support equine welfare, irrespective of where equine vets and their patients live and work.”
Carried out by the Royal Veterinary College (RVC), the Animal Health Trust (AHT) and Rossdales Equine Hospital, the study also revealed that the groups particularly at risk were native pony breeds and their crosses, as well as horses and ponies with a history of laminitis and those with lameness or soreness after routine hoof care.
This research, funded by World Horse Welfare, comes from the first ever online study that collected information on laminitis from a group of owners in real time.
The researchers say that the study is also the second largest to identify weight gain as a risk factor for laminitis. Data was collected from the owners of 1,070 horses and ponies in Great Britain, who reported their animal’s management, health and estimated weight via online questionnaires for 29 months.
Owners were encouraged to use a custom weight tracking tool designed by the study/research team to help regularly track changes in their animal’s weight and body condition. The uptake of this tool was high, with over half of participating owners using it.
The tool is freely available at: www.aht.org.uk/research/lameness/laminitis.
Other study findings included:
A high risk of laminitis was present in horses shod or trimmed at intervals of more than 8 weeks, and in those that took a long time to return to soundness after a bout of laminitis.
Diet, grazing management and health were factors closely associated with the development of laminitis and will be the subject of future investigation.
Researchers also noted that weight gain often occurred unintentionally, even when owners were aiming for their animals to maintain or lose it. This reiterates the need to consistently record weight and body condition in order to prevent undesirable weight gain.
Dr. Dee Pollard of the AHT, one of the study’s chief authors, said: "This is one of the largest, and the first, online laminitis studies where we collected regular information from the same group of owners in real-time. We assessed the relationship between laminitis and many potential management and health factors and identified those more likely to be present before a laminitis episode was reported.
"We now have good evidence to develop laminitis prevention guidelines, and a number of different avenues to explore in the future. We cannot emphasise enough how important systematic and regular weight and body condition monitoring are. It’s very easy to miss weight gain when you are just relying on your eyes and you see your horse or pony every day. You need to get hands on, feel for the fat deposits and take measurements, remember the figures don’t lie!"
Reference
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.
The recall was initiated because a visual inspection confirmed the possibility of particulate contamination which is not acceptable for an intravenous use preparation.
The recall is for the following batches only:
108AB Expiry 12/01/2023113H Expiry 16/03/2023
Ceva Animal Health Ltd is contacting veterinary surgeons, retailers and wholesale dealers to examine inventory and quarantine products subject to the recall.
For further information, contact Peter Kyte Business Unit Manager on +44 1494 781510.
5638 events were reported spontaneously, mainly by the marketing authorisation holder (61%), with the remainder largely reported by veterinary surgeons.
Of these, 5512 were reports of adverse reactions in animals: 829 concerning suspected lack of efficacy, 4638 concerning safety. The majority of reports concerned dogs (2927), cats (1426) and cattle (386).
In dogs, medicines for the control of epilepsy were most often suspected of not having performed as expected (80 reports) whilst vaccines were most commonly reported as having failed to work (71). However, the VMD points out that in many cases, vaccination failure was attributable to other causes (such as incomplete vaccination schedule).
In cats, flea spot-on products were most likely to be reported as not having worked (21). However, there are many reasons why owners may continue to see live fleas on their animal which are unrelated to product efficacy (such as reinfestation from the environment).
Notably, the majority of efficacy reports in horses (12/19) related to euthanasia products, which the report says should serve as a reminder that alternative means of euthanasia should always be available in case the chosen method does not proceed as planned.
Of the safety reports, 59.6% involved dogs, 31% cats, 4.9% horses and 3.9% rabbits. The majority concerned vaccines (1360 reports, most commonly general signs or symptoms, such as lethargy or pyrexia), parasiticides (472 reports, most commonly lethargy, emesis, inflammation/pruritus, depending on method of administration) and inflammation control (412 cases, most commonly emesis, renal insufficiency and diarrhoea, depending on the drug type).
There were 124 reports of adverse events in humans. Of those involving veterinary professionals (about a quarter):
The VMD says that reports of needle stick injuries involving vaccines with a mineral oil adjuvant are of particular concern, because they often fail to show that the injured party has received prompt and correct treatment, either because they are themselves unaware of the necessity for swift intervention, or because they do not take the product package information leaflet with them when seeking medical treatment.
Similarly, the VMD says that incidents involving injectable tilmicosin seem to be often dismissed as just a scratch, and that if you use these products, you should make sure you are fully aware of the warnings contained in the product leaflets.
To read the full report, visit: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/608968/PhV_Annual_Review_2015_v7.pdf
The nine-page booklet is being distributed electronically to all BEVA members, together with a guide on spotting some of the warning signs horses may display, written by equine veterinary surgeon and behaviourist Gemma Pearson.
A report commissioned by the BEVA in 2013 indicated that an equine vet could expect to sustain between seven and eight work-related injuries that impeded them from practicing, during a 30-year working life.
Data available from the Health and Safety Executive suggests that this is a very high number of injuries compared to other civilian occupations, including those working in the construction industry, prison service and the fire brigade.
The new guide has been produced ‘by horse vets for horse vets’ with BEVA members contributing their views, experiences and suggestions to early drafts.
It provides information for those handling and involved with equine veterinary care; to make workers consider the steps that they can take to make their activities as safe as reasonably possible by assessing a situation and implementing measures to limit the risk that vets and others are exposed to.
The guide also aims to challenge prevailing attitudes and culture. It outlines how to make ‘on the spot’ or ‘mental’ risk assessments and when to stop if a procedure becomes unsafe.
The guide is accompanied by an illustrated leaflet Signs of Increased Arousal Combined with a Negative Effective State. Written by Gemma Pearson, BVMS Cert AVP (EM) MRCVS who specialises in equine behaviour and learning theory, it explains signs of increased arousal including facial expressions, stance, movement and response.
David Mountford, CEO of BEVA said: "The new guidelines have been carefully developed to ensure that they are as pertinent, pragmatic and helpful as possible for vets in practice. Hopefully they will help to make the equine veterinary workplace a little safer."
The new guides can be downloaded at: https://www.beva.org.uk/workplacesafety
Kruuse UK has announced the launch of its new Mud Fever Kits for horses.
Kruuse says the launch follows independent studies last year by Aimi Duff BVM&S, MRCVS (Scott, Mitchell & Associates, Hexham) on the use of Manuka ND dressings for the treatment of Mud Fever.
The kit contains one complete treatment for two legs (or two complete treatments for one leg) including all dressings. There is also a step-by-step guide from the "Ask the Vet" series which explains best treatment protocol, designed to help veterinary surgeons dispense the kit directly to clients with confidence.
According to the company, the benefits of using medical grade Manuka Honey in the treatment of Mud Fever include:
Andrew Groom, Managing Director of Kruuse UK Ltd said: "We are delighted with the initial response to our unique Mud Fever Kits; such additions to our range continue to enhance the Kruuse commitment to equine wound care."
Kruuse has launched a range of seven specialized sterile surgical disposable drapes and gowns developed for the surgery team working in equine clinics or hospitals.
The company says its new surgical sets have been designed so they include a comprehensive set of sterile drapes, towels, instrument covers and adhesive tapes needed to perform particular procedures:
Andrew Groom, Managing Director, Kruuse UK Ltd. said: "This exciting new range of products increase the Kruuse's equine product portfolio and develop further our commitment to provide specialist species available products to support the veterinary practitioner."
Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.
Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.
New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast. Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.
A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.
Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk. The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
The successful candidates, who completed their studies during 2020 and passed the examination in November, are Lucy Wilson (pictured right), from Equibreed UK, Reading, Vanessa Austin, who works at at Vets4Pets, Northampton, and Donna Johnson, the Clinical Services Manager at The Pet Vet, Barnsley.
Lucy said: “I chose to do the CVPM to cement my knowledge of how to run our practice to the best of my ability and to provide the highest level of support to my colleagues. The CVPM resources, syllabus and experience have given me a thorough understanding of my skills and areas to develop. I cannot recommend the experience highly enough.”
Chair of the VMG Certification and Training Committee, Philippa Davies, said: “The CVPM exam tests candidates’ skills in operational management, prioritising, strategy, and thinking on your feet. It’s a gruelling assessment and holders are an elite group. We are delighted to welcome Vanessa, Donna and Lucy and congratulate them on their achievement.”
For more information, visit: https://www.vetmg.com/education/cvpm/
The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.
The VDC says that information from the survey will help inform discussions on the regulation of technicians.
The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.
The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:
Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.
"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.
"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."
Intervet/Schering-Plough Animal Health has reported that since launch, its diagnostic service RespCheck has identified infectious diseases in 15 per cent of all animals checked under the scheme.
Offered to qualifying practices for no charge and implemented by the Animal Health Trust (AHT), Intervet/Schering Plough set up RespCheck to help identify the cause of infectious respiratory problems in horses.
The RespCheck kit, which has been used to swab more than 700 horses since launch, consists of naso pharyngeal swabs, enabling two horses per yard or outbreak to be swabbed for a variety of diseases. These include equine influenza, equine herpesvirus, Streptococcus equi (strangles), pasteurella, rhinovirus and Streptococcus zooepidemicus. The swabs are sent to the AHT for analysis and the results returned direct to the vet.
John Dickerson from Chine House Equine Hospital in Leicestershire said: "The service is fantastic, made all the better by being completely free of charge! The benefits are two-fold. From the clinical perspective it means we can discount or treat potential infections in a more timely fashion; for instance, we use RespCheck to screen for any suspected infectious respiratory disease cases which enables us to deal with the problem, through quarantine and strict hygiene measures, helping to prevent the spread of the disease.
The other benefit is to our practice reputation and the standard of service we can offer. It's great to be able to provide owners with peace of mind without it costing more than our call out fee. By the time an owner calls the vet they are usually stressed and worried about their horses symptoms and need some reassurance, which is exactly what RespCheck gives them. We are confident that providing a diagnostic service that is completely free and that puts an owners mind at rest regarding the risk of an infection can only be a good thing for our practice reputation and customer care.
Last year, the service proved its worth when the screening of a recently imported horse showed the animal had equine influenza. I believe that had RespCheck not been employed, we would have had an outbreak in that particular yard."
Practices interested in knowing more about RespCheck should contact their local Intervet/Schering-Plough Veterinary Business Manager or phone the company's Veterinary Support Group on 01908 685685.
The researchers, from the Dick Vet Equine Hospital, University of Edinburgh, Newcastle University, Istituto Zooprofilattico Sperimentale delle Venezie, and the University of Padova found that affected horses have major abnormalities in the structure of their neuromuscular junctions, microscopic sites of communication between nerves and muscles that are crucial for normal muscle function.
These abnormalities are believed to represent a toxin specific signature, effectively a ‘smoking gun’, for a neurotoxic enzyme termed a phospholipase A2.
Work is now underway to definitively identify the source of the toxin, in the hope that it will lead to novel treatments and improved diagnostics for this devastating disease.
The researchers think the toxin is likely to be produced by a microbe such as a bacterium or fungus growing on the horse’s pasture during the cold and dry weather which commonly precedes the disease.
Neurotoxic phospholipase A2 toxins are also present in the venom of many poisonous snakes, and there are many similarities between the signs of grass sickness and those of snake envenomation.
While there is no suggestion that venomous snakes cause grass sickness, it is hoped that some of the drugs that are currently being developed to treat and promote nerve regeneration in people paralysed by snake venoms can aid recovery of horses from grass sickness.
The researchers say that the neurotoxin most likely also causes the apparently identical diseases (termed animal dysautonomias) which affect cats, dogs, hares, rabbits, llamas, alpacas and sheep, and that their finding contradicts the previous leading hypothesis that grass sickness is a form of botulism.
This breakthrough is summarised in an editorial in the January 2025 issue of the Equine Veterinary Journal (EVJ).
The editorial, by Bruce McGorum and colleagues, looks at the implications of their article 'Equine grass sickness is associated with major abnormalities in the ultrastructure of skeletal neuromuscular junctions2".
Bruce said: “Identifying a probable cause of Equine Grass Sickness represents a significant breakthrough.
"We hope that this discovery will lead to novel treatments and improved diagnostics for this devastating condition.
"We are very grateful for the generous support we have received from horse owners, veterinary surgeons, scientists, charities and funding bodies.”
Bruce's editorial is currently available on Early View, free for 12 weeks, and will also be published in the January 2025 print issue of the EVJ.
The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.
One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.
Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.
The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.
Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.
Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.
The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.
Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.
"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.
"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."